Autoantibody Biomarker Panel for Early SCLC Blood Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for early detection of small cell lung cancer (SCLC) are inadequate, as there is no reliable blood test, and imaging techniques are insufficient due to the aggressive nature and mediastinal location of SCLC, leading to late-stage diagnoses with limited treatment options.
Innovation Solution
Development of a biomarker detection panel comprising autoantibody molecules that can detect SCLC with high sensitivity and specificity by identifying autoantibody-autoantigen complexes in a sample, using a method that includes contacting the sample with at least two autoantibody molecules capable of detecting SCLC-associated proteins, glycoproteins, and complexes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging techniques are used for SCLC detection, then mediastinal location and aggressive nature of SCLC are factors, but early detection sensitivity is insufficient leading to late-stage diagnosis
Solution Approach 1:
The patent detects autoantibodies and autoantibody-autoantigen complexes in the blood before the tumor reaches a clinically detectable size. This preliminary detection approach allows identification of SCLC at the microscopic stage, potentially years before clinical symptoms appear, thereby resolving the contradiction between detection sensitivity and diagnosis timing.
Solution Approach 2:
The patent uses autoantibodies and autoantibody-autoantigen complexes as intermediary biomarkers that reflect the presence of microscopic SCLC tumors. These biomarkers serve as mediators between the undetectable microscopic tumor and clinical detection methods, enabling early identification before the tumor mass becomes clinically visible.
2Reliability
If blood tests are developed for SCLC detection, then early detection capability improves, but currently no reliable blood test exists due to lack of validated biomarkers
Solution Approach 1:
The patent identifies and validates specific parameters - autoantibodies against particular autoantigens - as reliable biomarkers for SCLC detection. By focusing on these specific parameter changes in the immune response, the patent establishes a reliable blood test foundation that overcomes the previous lack of validated biomarkers.
3Reliability
If SCLC is detected at extensive stage, then current treatment options are available, but survival benefit is limited due to aggressive disease progression
Solution Approach 1:
By detecting SCLC at the microscopic stage through autoantibody analysis, the patent enables treatment initiation before extensive stage progression. This preliminary detection and subsequent early treatment can prevent aggressive disease progression, potentially curing approximately 20% of limited stage SCLC patients who would otherwise progress to extensive stage with limited treatment options.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biomarker panel achieves sensitivity and specificity of at least 75% in detecting SCLC, allowing for early-stage identification and potential curative treatment, with markers effective up to two years prior to clinical diagnosis.
Implementation Method 1
contacting a sample from a subject suspected of being at-risk of acquiring or having SCLC with at least two autoantibody molecules capable of detecting molecules provided herein, such as in Tables 1B, 2A, 2B, 3 and 4, and detecting binding of SCLC autoantibody-antigen complexes
Data Source
AI summary
Disclosed herein are high performance biomarkers and panel for small cell lung cancer (SCLC) early detection useful for identifying, diagnosing and treating SCLC patients at an early stage. The method of detecting and diagnosing small cell lung cancer (SCLC) includes contacting a sample from a subject suspected of being at-risk of acquiring or having SCLC with at least two SCLC-specific autoantibody molecules and detecting binding of four different protein types—SCLC autoantibody-antigen complexes, SCLC uncomplexed autoantibodies, SCLC associated proteins and SCLC glycoproteins—in the sample, thereby detecting SCLC in the subject.